



Markets
/
Stocks
/
nasdaq-ixhl
/

Incannex Healthcare Inc

IXHL

View Detailed Chart

0.152USD

-0.458-75.10%

Close 04/29, 16:00（ET）Quotes delayed by 15 min

2.70MMarket Cap

LossP/E TTM



Incannex Healthcare Inc

0.152

-0.458-75.10%

Company

Intraday

30m

Today

-75.10%

5 Days

-72.92%

1 Month

0.00%

6 Months

0.00%

Year to Date

0.00%

1 Year

0.00%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(2)

Neutral(0)

Buy(0)

Indicators

Sell(0)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

RSI(14)

STOCH(KDJ)(9,3,3)

ATR(14)

CCI(14)

Williams %R

TRIX(12,20)

StochRSI(14)

Moving Average

Sell(2)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

MA10

MA20

MA50

MA100

MA200

News

More news coming soon, stay tuned...

Company

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.

Company codeIXHL

CompanyIncannex Healthcare Inc

CEOMr. Joel Latham

Website